Pdf dabigatran etexilate in atrial fibrillation patients. Dabigatran etexilate is rapidly absorbed after oral administration and is converted to dabigatran. Relyable long term multicenter extension of dabigatran treatment in patients with atrial fibrillation who completed re ly trial the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The openlabel study involved 120 patients from nine countries and looked to evaluate the suitability of dabigatran etexilate and warfarin for the treatment and secondary. A total of 2,564 patients were randomized to receive either 6 months of dabigatran 150 mg twice daily or doseadjusted. The rely randomised evaluation of longterm anticoagulant therapy trial showed that dabigatran 150 mg twice daily was more effective. The annual rates of stroke or systemic embolism were 1. These data could provide insights into intraindividual variability in trough plasma dabigatran concentrations over time. Dabigatran etexilate pradaxa, a prodrug, is a new oral competitive direct. Diener hc, connolly sj, ezekowitz md, wallentin l, reilly pa, yang s, xavier d, di pasquale g, yusuf s. Learn vocabulary, terms, and more with flashcards, games, and other study tools. The use of dabigatran in general practice bpj issue 38. This large, randomized, doubleblinded, controlled trial included 18,1 patients from 951 clinical centers in 44 countries. The rely trial was a prospective, randomized trial investigating the effectiveness and safety of 2 doses of dabigatran in preventing stroke and systemic embolic events sees in patients with nonvalvular af compared with warfarin.
This commentary refers to dabigatran versus warfarin in patients with atrial fibrillation, by s. Randomized evaluation of longterm anticoagulant therapy. Randomized evaluation of long term anticoagulant therapy. Find, read and cite all the research you need on researchgate. Efficacy and safety of dabigatran versus warfarin from the. Dabigatran has a predictable pharmacokinetic profile, allowing. All patients provided written informed consent before study entry. Realworld study reassures on dabigatran stroke, ich rates. Efficacy and safety of dabigatran versus warfarin from the rely trial. Pdf clinical utility of dabigatran in united arab emirates a pharmacovigilance study abdulla shehab, frcp, phd, asim a. The rely study 8 is a trial of 18 000 patients with atrial fibrillation who were randomized between warfarin or one of two doses of dabigatran etexilate 110 mg b. The rely study demonstrated that compared to warfarin, highdose dabigatran reduces stroke risk without increasing the risk of major. Therapy rely clinical trial, dabigatran 150mg twice daily was shown to be noninferior to warfarin for the prevention of stroke and systemic embolism 4. Learning more from the dabigatran concentrations in the re.
Dabigatran etexilate is a prodrug that is rapidly converted to active moiety dabigatran. Dose identification using pharmacokinetic modeling and simulation. The recover trial, published in nejm in 2009, was a randomized, doubleblind, noninferiority trial comparing dabigatran with warfarin in the treatment of acute venous thromboembolism. Dabigatran versus warfarin for atrial fibrillation in. The benefits of 150 mg dabigatran at reducing stroke, 110 mg dabigatran at reducing bleeding, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centres quality of inr control. Dabigatran etexilate is a prodrug of dabigatran, a specific, competitive, and reversible inhibitor of thrombin.
Mortality rates were similar for the 2 dabigatran doses. The rely trial showed that dabigatran 150 mg twice daily was superior to warfarin at reducing stroke or systemic embolism. Kent, janice pogue, judith spahr, andreas clemens, herbert noack, hanschristoph diener, lars wallentin, salim yusuf, stuart j. Antithrombotic trials in atrial fibrillation, the rely study. Relyable long term multicenter extension of dabigatran. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment. In this noninferiority trial, we randomly assigned 18,1 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion. Trials are underway to determine the effectiveness of dabigatran for longterm prophylaxis. Comparative effectiveness and safety of warfarin and. The objective of this analysis was to characterize the population pharmacokinetics poppk of. The goal of the trial was to evaluate the efficacy and safety of two doses of the novel oral direct thrombin inhibitor dabigatran compared with warfarin among patients with atrial fibrillation.
In patients with atrial fibrillation af, treatment with the direct thrombin inhibitor dabigatran etexilate is safe and effective at twicedaily doses of. Efficacy and safety of dabigatran compared to warfarin at. In the rely randomized evaluation of longterm anticoagulant th erapy study, a lifethreatening bleed bleeding that met one or more of the following criteria. Dabigatran was the first direct oral anticoagulant approved for stroke prevention in patients with nonvalvular atrial fibrillation nvaf. Dabigatran etexilate a novel, reversible, oral direct. Major bleeding primary endpoint occurred at rates of 3. The approval was based on a clinical trial that included over 18,000 patients. Randomized evaluation of long term anticoagulant therapy re ly comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the eu and several other countries for the prevention of venous thromboembolism after elective hip and knee replacement, and is in advanced clinical development for other thromboembolic disorders.
The results showed that, relative to warfarin, dabigatran 110 mg twice daily. Connolly, longterm evaluation of dabigatran 150 vs. The study participants represented a select group of people and the outcomes of treatment with dabigatran may be different in a real world setting. Appendix and the supplementary ap pendix, available with the full text of this article at. If you are unsure about dabigatran, do not change from warfarin without seeking specialist advice avoid changing patients from warfarin to dabigatran unless there is a clear advantage. Dabigatran versus warfarin in patients with atrial.
Dabigatran, 150 mg, was superior to warfarin for stroke prevention in all types of af paroxysmal hr 0. Dabigatran versus warfarin in patients with atrial fibrillation. Clinical trial data and realworld assessments pradaxa. The original study findings, published in 2009, demonstrated that, compared with warfarin, 150 mg dabigatran was superior, and 110 mg dabigatran was similar, in the prevention of thromboembolism. Dabigatran etexilate is a prodrug that is rapidly absorbed following oral administration and converted by nonspecific plasma and hepatic esterases into the active moiety, dabigatran. In the re ly study, a subgroup of those on dabigatran etexilate contributed additional blood samples at 3, 6, and 12 months after enrollment 1. In the re ly study, a subgroup of those on dabigatran etexilate contributed additional blood samples at 3, 6, and 12 months after enrollment.
Pradaxa clinical trial data and realworld assessments the safety of pradaxa has been studied extensively. The study was funded by boehringer ingelheim and was coordi. The rely randomized evaluation of longterm anticoagulation therapy study evaluated the benefits and risks of dabigatran compared with those of warfarin in 18,1 patients with nvaf 4. Dabigatran is eliminated mainly unchanged 8085% of the dose and partially as the glucuronide 20% via renal glomerular. John camm st georges university of london, london, uk online publishaheadofprint 21 september 2009 this commentary refers to dabigatran versus warfarin in patients with atrial. The study was approved by all appropriate national regulatory authorities and ethics committees. There were no differences in the rates of major bleeding among the different af subgroups.
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke. The re ly trial, which had a study population of 18 000 patients, compared 2 doses of dabigatran etexilate with warfarin in the largest randomized controlled trial of antithrombotic therapy for. Center average ttr in the warfarin arm rosendaal method applied as a proxy for all patients in each center statistics. Prospective, multicentre, parallelgroup, noninferiority trial re ly study. Dabigatran etexilate is the first and only novel oral anticoagulant with controlled longterm clinical trial data extending beyond 6 years of ongoing treatment. In questioning the reliability of the re ly trial results, tsang and others 1 unfortunately based their concerns on a misinterpretation of the data that were published in the original trial report. Warfarin was within therapeutic range 66% of the study period active. Conversion to dabigatran involves the hydrolysis of two functional groups. In 2010, pradaxa was the first fdaapproved alternative to warfarin to reduce risk of stroke in atrial fibrillation afib not caused by a heart valve problem. Randomisation and masking in re ly patients were randomly assigned 1. Population pharmacokinetic analysis of the oral thrombin.
Retrospective cohort study of the efficacy and safety of. Pradaxa dabigatran etexilate mesylate capsules for oral. The study found a comparable rate of ischemic stroke and overall bleeding with dabigatran and warfarin, but dabigatran was associated with a reduced rate of intracranial hemorrhage, a raised risk. There are some drug interactions with dabigatran, for example proton pump inhibitors reduce absorption, but the only drug truly contraindicated for patients on dabigatran is quinidine. The longterm multicenter extension of dabigatran treatment in patients with atrial fibrillation relyable study was designed to provide additional information on the longterm effects of the 2 doses of dabigatran in patients completing re ly by extending the followup of patients on dabigatran from a mean of 2 years at the end of re ly by an. Dabigatran versus warfarin in patients with atrial fibrillation nejm. Discontinue dabigatran, check crcl, tt, aptt and discuss with haematologist or cardiologist. Comparison of dabigatran and warfarin in patients with. Australian public assessment report for dabigatran.
The rely trial, which had a study population of 18 000 patients, compared 2 doses. The re ly study 8 is a trial of 18 000 patients with atrial fibrillation who were randomized between warfarin or one of two doses of dabigatran etexilate 110 mg b. The relyable study followup visits occurred at 4, 8, 18, and 23 months, and the final visit occurred at 28 months. The randomized evaluation of longterm anticoagulation therapy rely was a randomized trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner. Pdf efficacy and safety of dabigatran etexilate vs.
Dabigatran versus warfarin for stroke prevention in. Dabigatran is predominantly excreted unchanged via the kidneys pharmacokinetics 10. Its halflife is about 8 hours after a single dose and 1417 hours after multiple doses. For all vascular events, nonhaemorrhagic events, and mortality, advantages of dabigatran were greater at sites with poor inr control than at those with good. The longterm multicenter observational study of dabigatran treatment in patients with atrial fibrillation relyable study.
122 796 989 1493 324 64 1108 739 678 1075 310 1178 666 761 939 1568 1315 761 730 1284 441 1102 1018 1448 1353 259 82 1518 1499 1076 1299 1109 242 475 1061 1101 1398 145 36